Articles by Michael B. Atkins, MD
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
Dr. Michael Atkins discusses long-term results of IO/TKI combinations for metastatic RCC and how they may influence debate.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
The panel discusses treatment options in the refractory RCC setting.
The panel discusses what is most exciting to them in the frontline RCC field.
The panel discusses toxicity management and use of precision medicine.
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
The panel discusses the approach to frontline treatment selection for patients with RCC.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.